Myrexis (MYRX) suspends development activity on all its programs, saying it's been unsuccessful...

|By:, SA News Editor

Myrexis (MYRX) suspends development activity on all its programs, saying it's been unsuccessful to date in identifying and attracting third parties to whom it could out-license or sell assets for further development. In February, the company announced that it had suspended development activity on all of its preclinical and clinical programs, and retained Stifel Nicolaus Weisel to assist in reviewing and evaluating strategic alternatives.